Fraunhofer Institute for Cell Therapy and Immunology IZIWe connect biomedical research with application: Our translation-oriented bioanalytics accelerates the path from laboratory innovation to clinical and industrial implementation – with validated methods, scalable workflows, and regulatory understanding.
Translation-oriented bioanalytics
Evaluation of therapies in the preclinical phase
We assess efficacy, safety, and dose-response relationships in validated in vitro and ex vivo models and support robust go / no-go decisions.
Development of novel companion diagnostics and technologies for patient monitoring
From biomarker identification to assay design and analytical / clinical validation, we develop CDx solutions and monitoring technologies for precise therapy decisions. In addition to classical methods, we also use innovative non-invasive or label-free technologies such as gas analysis (GC-IMS) and deformability cytometry.
Quality control in the production of biological materials
We complement your established QC panels with non-invasive or label-free technologies such as gas analysis (GC-IMS) and deformability cytometry.
Implementation of new analytical technologies in manufacturing processes for biological materials
Technology transfer, qualification, and integration of analytics into GMP-compliant environments, including SOP creation, training, and data integration.
Design and execution of market-relevant proof-of-concept demonstration projects for analytical instruments
Application-oriented studies with clear performance indicators (sensitivity, specificity, throughput, cost) to accelerate product validation and market entry for laboratory analytical instruments.
Retrospective studies on biobank cohorts of patients / donors
Methodically sound evaluation of existing biobank samples and data for biomarker validation, hypothesis generation, and support of regulatory dossiers. For this, we utilize our entire portfolio of modern analytical technologies, including flow and deformability cytometry.